All Oncology News

First-line ficerafusp alfa at 2000 mg every 2 weeks plus pembrolizumab was deemed safe and effective in recurrent or metastatic HPV-negative HNSCC.

The NCCN guidelines endorse frontline sacituzumab govitecan alone for PD-L1–negative mTNBC and in combination with pembrolizumab for PD-L1–positive mTNBC.

Mayo Clinic researchers have developed a promising new way to deliver treatment directly to cholangiocarcinoma.

Patients with HLA-A*02–negative, HER2-positive early breast cancer experienced a recurrence rate of less than 1% when treated with GLSI-100.GLSI-100

The NCCN guidelines in bladder cancer now include nogapendekin alfa inbakicept plus BCG for BCG-unresponsive NMIBC with papillary-only disease.

Nicole Lamanna, MD, discusses the implications of the FDA approval of frontline acalabrutinib plus venetoclax in CLL.

Retrospective data showed longer durations of bridging therapy with a BTK inhibitor improved CAR T-cell therapy response in relapsed/refractory DLBCL.

Acalabrutinib/lenalidomide in combination with rituximab or obinutuzumab generated uMRD6 CRs in previously untreated mantle cell lymphoma.

Isaac Y. Kim, MD, PhD, MBA, and Anthony V. D'Amico, MD, PhD, discuss radiotherapy, surgery, and emerging strategies in mHSPC.

A detailed blueprint of tumor cell diversity could guide more precise, targeted treatments for supratentorial ependymomas.

Will the FDA approve bezuclastinib for the treatment of patients with nonadvanced systemic mastocytosis?

Vincent Picozzi, MD, discusses the importance of the FDA approval of Optune Pax for TTField development in locally advanced pancreatic cancer.

The top 5 OncLive TV videos of the week cover insights in colorectal cancer, breast cancer, bladder cancer, and more

Toni K. Choueiri, MD, discusses new data with adjuvant belzutifan plus pembrolizumab for the treatment of patients with clear cell RCC.

A drug withdrawal in follicular lymphoma and epithelioid sarcoma, a CRL in lung cancer, and priority review in breast cancer highlight this week's top oncology news.

Tycel Phillips, MD, discusses how CAR T-cell therapies and bispecific antibodies could further affect mantle cell lymphoma management.

PMD-026 inhibits RSK to block tumor growth signals and ER activity, a potential strategy to overcome CDK4/6 inhibitor resistance in breast cancer.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Although the 5-year survival rate has improved to about 13 percent, pancreatic cancer remains one of the deadliest cancers, often diagnosed at advanced stages with limited treatment options.

The phase 3 TACTI-004 trial in patients with NSCLC has been discontinued in accordance with an independent data monitoring committee recommendation.

PSA50 outcomes with lutetium Lu-177 vipivotide tetraxetan did not differ by race in patients with mCRPC.

PSA decline or control was not found to be concordant with PSMA tumor volume changes among enzalutamide-treated patients with BCR prostate cancer.

Venetoclax plus decitabine/cedazuridine after a venetoclax-based RIC regimen was effective and safe in myelodysplastic syndromes or acute myeloid leukemia.

Lutetium-177 rosopatamab tetraxetan plus SOC therapies was safe and tolerable in patients with PSMA-positive mCRPC.

Unlike conventional radiation therapy systems, adaptive radiotherapy creates a new plan for each treatment session, allowing clinicians to deliver larger doses of radiation to tumors more safely.

Neha Vapiwala, MD, FACR, FASTRO, FASCO, unpacks notable updates from ASCO GU and discusses a trend toward individualized therapy in prostate cancer.

Marwan G. Fakih, MD, discusses the implications of the FDA approval of retifanlimab plus chemotherapy for the evolving role of immunotherapy in SCAC.

Researchers at Dana-Farber Cancer Institute show why SCLC stays out of reach of the immune system, even when cancer cells are vulnerable to immune attack.

Response to evorpacept plus zanidatamab was predicted by high levels of CD47 expression in patients with HER2-positive metastatic breast cancer.

Rachna T. Shroff, MD, MS, FASCO, discusses how this “sea change” has coincided with evolving considerations for frontline selection in pancreatic cancer.